Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr 26;108(17):6951-6.
doi: 10.1073/pnas.1012899108. Epub 2011 Apr 11.

Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro

Affiliations

Cisplatin binds human copper chaperone Atox1 and promotes unfolding in vitro

Maria E Palm et al. Proc Natl Acad Sci U S A. .

Abstract

Cisplatin (cisPt), Pt(NH(3))(2)Cl(2), is a cancer drug believed to kill cells via DNA binding and damage. Recent work has implied that the cellular copper (Cu) transport machinery may be involved in cisPt cell export and drug resistance. Normally, the Cu chaperone Atox1 binds Cu(I) via two cysteines and delivers the metal to metal-binding domains of ATP7B; the ATP7B domains then transfer the metal to the Golgi lumen for loading on cuproenzymes. Here, we use spectroscopic methods to test if cisPt interacts with purified Atox1 in solution in vitro. We find that cisPt binds to Atox1's metal-binding site regardless of the presence of Cu or not: When Cu is bound to Atox1, the near-UV circular dichroism signals indicate Cu-Pt interactions. From NMR data, it is evident that cisPt binds to the folded protein. CisPt-bound Atox1 is however not stable over time and the protein begins to unfold and aggregate. The reaction rates are limited by slow cisPt dechlorination. CisPt-induced unfolding of Atox1 is specific because this effect was not observed for two unrelated proteins that also bind cisPt. Our study demonstrates that Atox1 is a candidate for cisPt drug resistance: By binding to Atox1 in the cytoplasm, cisPt transport to DNA may be blocked. In agreement with this model, cell line studies demonstrate a correlation between Atox1 expression levels, and cisplatin resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Near-UV CD-monitored titrations of metals to apo/metallated Atox1 (pH 6, 20 °C): (A) 50 μM apo-Atox1 and 50 μM Cu-Atox1 (1∶1); (B) CisPt (up to fivefold excess as indicated) added to 50 μM Cu-Atox1; (C) CisPt (up to fivefold excess as indicated) added to 50 μM apo-Atox1; (D) Cu (up to fivefold excess as indicated) added to 50 μM cisPt-Atox1 (1∶1).
Fig. 2.
Fig. 2.
(A) Far-UV CD spectra as a function of time (0 h to 14 d) for apo-Atox1 (50 μM) mixed with 5 eq cisPt and incubated at 20 °C. Time points are 0, 5, 8, 24, 29, 32, 48, 73, 144, 168, 240, and 336 h. (B) CD changes at 220 nm (at 20 °C) plotted as a function of time for apo-Atox1 alone, apo-Atox1 (50 μM) mixed with 1 or 5 eq cisPt, and for Cu-Atox1 (50 μM) mixed with 1 or 5 eq cisPt. Also shown are a few time points for 0.5 mM apo-Atox1 mixed with 5 eq cisPt.
Fig. 3.
Fig. 3.
Interaction between cisPt and apo-Atox1 probed with NMR spectroscopy. 1H-15N HSQC NMR spectra of apo-Atox1 (green contours) superimposed on that of a 2∶1 cisPt:Atox1 complex (orange contours). Selected peaks corresponding to the folded cisPt:Atox1 complex (*) and unfolded species (#) are indicated.
Fig. 4.
Fig. 4.
CisPt-induced unfolding of Atox1. 1H-15N HSQC NMR spectra acquired after 4, 8, and 16 h after mixing of a 5∶1 cisPt:apo-Atox1 sample.

Similar articles

Cited by

References

    1. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 2007;33:9–23. - PMC - PubMed
    1. Ivanov AI, et al. Cisplatin binding sites on human albumin. J Biol Chem. 1998;273:14721–14730. - PubMed
    1. Zhao T, King FL. Direct determination of the primary binding site of cisplatin on cytochrome C by mass spectrometry. J Am Soc Mass Spectrom. 2009;20:1141–1147. - PubMed
    1. Calderone V, Casini A, Mangani S, Messori L, Orioli PL. Structural investigation of cisplatin-protein interactions: Selective platination of His19 in a cuprozinc superoxide dismutase. Angew Chem Int Ed Engl. 2006;45:1267–1269. - PubMed
    1. Casini A, et al. ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme. Chem Commun (Camb) 2007;14:156–158. - PubMed

Publication types

MeSH terms

LinkOut - more resources